CAR-T Cell Therapy Market to Grow at a robust CAGR of 64.66% During the Forecast Period
Increasing prevalence of different types of Cancer is driving
the growth in Global CAR-T Cell Therapy market in the forecast period, 2022-2027.
According to TechSci Research report, “CAR-T Cell therapy Market - Global Industry Size,
Share, Trends, Opportunity, and Forecast, 2017-2027”, the global CAR-T Cell therapy market stood
at USD 1709.00 Million in 2021 and is expected to grow at a CAGR of 64.66%
during the forecast period on account of growing prevalence of different types
of Cancer.
The continuously approval of new CAR-T Cell therapies from different
companies is expected to support the market growth through 2027. The growing
prevalence of various types of Cancer such as Diffused Large B-Cell Lymphoma
(DLBCL), Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM), Breast Cancer,
Acute Lymphoblastic Leukemia (ALL), and many others has significantly increased
the patient pool worldwide suffering from these diseases.
This in turn has significantly increased the demand for various CAR-T
Cell therapies. These CAR-T Cell therapies can be used for treatment of these
types of Cancer. For Instance, in September 2021, China’s National
Medical Products Administration (NMPA) has approved its CAR-T cell
immunotherapy of JW Therapeutics’ Relmacabtagene autoleucel injection by the
brand name of relma-cel.
Apart of that, increase in the number of CAR-T Cell Therapy Clinical
Studies also supporting the market growth of CAR-T Cell therapy market. For
instance, 1304 ongoing or upcoming CAR-related trials registered at
ClinicalTrials.gov as of December 22, 2020. Out of which total of 433 trials
(56%) were from China and 288 from the US (37%).
However, the high cost of CAR-T Cell Therapy leads to affordability
constraints, especially in developing countries of Asia Pacific, South America,
and Middle East & Africa. Also, stringent regulatory scenario and policies
for launching and marketing CAR-T Cell therapy are expected to significantly hamper
the market growth.
The FDA is very strict when it comes to the approvals for them. Also,
countries that do not follow FDA but have their own regulatory associations are
also very strict for product approvals and their market launch. The regulatory
framework is quite strict when it comes to product recalls. Furthermore, lack
of awareness pertaining to the availability and use of CAR-T Cell therapy among
the population, especially in the developing and under-developed countries, is
expected to hamper the market growth during the forecast period.
Browse over 173
market data Figures and 13 market data Tables spread through 283 Pages and an in-depth TOC on "Global
CAR-T Cell therapy Market"
https://www.techsciresearch.com/report/car-t-cell-therapy-market/5168.html
The Global CAR-T Cell Therapy market is segmented based on by product type, tumor type, indication, treatment type,
targeted antigen, end user, company, and regional distribution.
Based on product type, the market can be split into YESCARTA
(axicabtagene ciloleucel), KYMRIAH (tisagenlecleucel), TECARTUS (brexucabtagene
autoleucel), BREYANZI (lisocabtagene maraleucel), ABECMA (idecabtagene
Vicleucel), and Others. YESCARTA (axicabtagene ciloleucel) dominates the market
of CAR-T Cell therapy by accounting the share of 49.27% in 2021. This mainly
due to the approval of Yescarta in different Countries such as China, Japan,
and others.
Based on tumor type, the market is divided into Hematological
Malignancies and Solid Tumors. Hematological Malignancies dominates
the market most of the CAR-T Cell therapy which get approved are used to treat Hematological
Malignancies.
Based on indication, the market can be divided into Diffused Large B-Cell Lymphoma (DLBCL),
Acute Lymphoblastic Leukemia (ALL), Follicular Lymphoma (FL), Mantle Cell
Lymphoma (MCL), and Others. Diffused Large B-Cell Lymphoma
(DLBCL) dominates the market followed by Acute Lymphoblastic Leukemia (ALL) as
due to increase in the number of Diffused Large B-Cell Lymphoma (DLBCL) cases
and mainly all approved CAR-T Cell therapies are used to treat Lymphoma cancer.
In terms of treatment type, the market divided into Single Treatment and
Combination Treatment. Based on targeted antigen, the market is segmented into CD 19,
BCMA, and Others. In terms of end user, the market is segmented into Hospitals,
Specialty Clinics, Ambulatory Surgical Centers, Others.
Key market players in the Global CAR-T Cell therapy market include:
·
Gilead Sciences Inc
·
Novartis International AG
·
Bristol Myers Squibb Company
·
AbbVie Inc.
·
Cellectis SA
·
Amgen Inc
·
Pfizer Inc
·
Merck & Co. Inc.
·
Intellia Therapeutics Inc.
·
Poseida Therapeutics Inc
·
Johnson & Johnson
·
Allogene Therapeutics Inc
·
Autolus Therapeutics PLC
·
Humanigen, Inc
·
Sangamo Therapeutics, Inc
Global CAR-T Cell therapy
market is consolidated with a lot of well-established players having presence
in several countries: with several domestic players possessing leadership in
certain regions and countries, among others. Gilead Sciences Inc. holds
the highest market share and is among the top five market players globally. Novartis
International AG ranks second in terms of market share in the overall CAR-T
Cell therapy market. The company has a strong presence worldwide and a huge Kymirah
brand value. People in emerging countries are also aware about the presence,
product portfolio and business of the company and are preferring it over other
competitor brands.
Additionally, there are other
prominent players that are doing research relates to CAR-T Cell therapies such
as AbbVie Inc., Cellectis SA, Amgen Inc, Pfizer Inc, Merck & Co. Inc.,
Intellia Therapeutics Inc., Poseida Therapeutics Inc, Johnson & Johnson,
Allogene Therapeutics Inc, Autolus Therapeutics PLC, Humanigen, Inc, Sangamo
Therapeutics, Inc, and among others. For instances, Johnson & Johnson and
partner Legend Biotech are expecting an FDA decision for their first CAR-T
product, cilta-cel.
Download Sample Report @
https://www.techsciresearch.com/sample-report.aspx?cid=5168
Customers can also request for 10% free customization on this report.
“The
North America dominates the market of CAR-T Cell therapy. This can be
attributed to the large and growing cancer population in the region, which is
susceptible to different kinds of cancers, especially in countries like United
States, Canada, and Mexico. Additionally, all the approved CAR-T Cell first
approved by US-FDA which is expecting to support market growth. For instance,
“all 5 FDA-approved commercial CAR-T cell therapies are available in the United
States. Also, an increasing number of
healthcare and pharmaceutical companies are focusing on the development and
commercial manufacturing of CAR T-cells in the country and growing awareness
and adoption of personalized treatments are expected to support the market
growth through 2027,” said Mr. Karan Chechi, Research Director with TechSci
Research, a research based Global management consulting firm.
“Global
CAR-T Cell Therapy Market - Global Industry Size, Share, Trends, Opportunity
and Forecast, 2017-2027 Segmented By Product Type (Yescarta (Axicabtagene
Ciloleucel), Kymriah (Tisagenlecleucel), Tecartus (Brexucabtagene Autoleucel),
Breyanzi (Lisocabtagene Maraleucel), Abecma (Idecabtagene Vicleucel), Others),
By Tumor Type (Hematological Malignancies, Solid Tumors), By Indication
(Diffused Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL),
Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Others), By Treatment
Type (Single Treatment, Combination Treatment), By Targeted Antigen (CD 19,
BCMA (B-Cell Maturation Antigen), Others), By End User (Hospitals, Specialty
Clinics, Ambulatory Surgical Centers, Others), By Region, By Company”, has evaluated the future growth
potential of global CAR-T Cell therapy and provides statistics &
information on market size, structure and future market growth. The report
intends to provide cutting-edge market intelligence and help decision makers
take sound investment decisions. Besides, the report also identifies and
analyzes the emerging trends along with essential drivers, challenges, and
opportunities in global CAR-T Cell therapy market.
Contact
Mr.
Ken Mathews
708
Third Avenue,
Manhattan,
NY,
New
York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com/